City
Epaper

License of 14 Patanjali products cancelled, criminal complaint filed against Ramdev, Balkrishna, Uttarakhand govt tells SC

By IANS | Updated: April 29, 2024 23:45 IST

New Delhi, April 29 The Uttarakhand government, in an affidavit, told the Supreme Court that it has granted ...

Open in App

New Delhi, April 29 The Uttarakhand government, in an affidavit, told the Supreme Court that it has granted permission to file a complaint against Baba Ramdev's Divya Pharmacy and Patanjali Ayurved Ltd. for repeated violations of the drug advertisements law and suspended manufacturing licenses for 14 of their products.

In the affidavit, the Uttarakhand government submitted that its State Licencing Authority has issued a public notice intimating that publication of advertisements contrary to the law would entail strict disciplinary and legal action, including fine, imprisonment, or both.

The affidavit filed by the State Licensing Authority, Ayurvedic and Unani Services, stated that it has granted permission on April 12 to the Drug Inspector, Haridwar for filing a complaint against Divya Pharmacy and Patanjali Ayurved Ltd. for repeated violations of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

"The SLA issued an order, dated April 15, 2024, to Divya Pharmacy and Respondent No. 5-Patanjali Ayurved Ltd., stating therein that the manufacturing licenses for 14 of their products, namely 'Swasari Gold', 'Swasari Vati, Bronchom', 'Swasari Pravahi', 'Swasari Avaleh', 'MuktaVati Extra Power', 'Lipidom', 'Bp Grit', 'Madhugrit', 'MadhunashiniVati Extra Power', 'Livamrit Advance', 'Livogrit', 'Eyegrit Gold' and ‘Patanjali Drishti Eye Drop’, are suspended with immediate effect under Rule 159(1) of The Drugs and Cosmetics Rules, 1945," it said.

"The District Ayurvedic and Unani Officer, Haridwar filed a criminal complaint before the Chief Judicial Magistrate, Haridwar against Swami Ramdev, Acharya Balkrishna, Divya Pharmacy and Patanjali Ayurved Limited under Sections 3, 4 and 7 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954," the affidavit added.

The SLA said that it will continue to take all due and further steps against Divya Pharmacy and Patanjali Ayurved Ltd, as per the procedure prescribed in law and the directions issued by the Supreme Court.

In an order passed on April 10, the apex court had ordered the then Joint Director of the State Licencing Authority and all the officers holding the post of District Ayurvedic and Unani Officer, Haridwar from 2018 till date to file their respective affidavits explaining the inaction on their part.

The Indian Medical Association has sought action against Patanjali for violation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, which prohibits the advertisement of certain products for the treatment of specified diseases and disorders, including diabetes, heart diseases, high or low blood pressure and obesity.

The ayurvedic company had earlier made an undertaking before the Supreme Court saying that it would not make any casual statements claiming the medicinal efficacy of its products or advertise or brand them in violation of law and would not release any statement against any system of medicine to the media in any form.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NationalThis vote is an opportunity to take revenge for insult to President Murmu: HM Shah tells Bengal's tribal community

InternationalCeasefire in Lebanon part of agreement, says Iranian FM Spokesperson for peace talks with US: Iran Media

Other SportsIPL does not just find talent, it forces talent to declare itself: Lalit Modi

CricketDown the track, in the 'V' position: Abhishek shows two technical powers during stroke-filled 74 against PBKS

BusinessGL Bajaj Strengthens its Standing as a Leading Innovation and Entrepreneurship Hub with 140 Startups Valued at Rs. 500 Crore

Health Realted Stories

HealthGovt mulls cough syrups ban for kids under 2 amid safety concerns: Report

Health‘India Pharma 2026’ to drive India’s transition to global innovation hub

HealthCARI Bengaluru 1st CCRAS institute to get landmark ISO accreditation in biochemistry, haematology

HealthThis common nutrient could supercharge cancer treatment: Study

HealthNo Sugar For 15 Days? Here's How Your Body Will Transform